The AI in endoscopy market size was valued at USD 2.87 billion in 2025 and is projected to grow from USD 3.50 billion in 2026 to USD 17.15 billion by 2034, registering a CAGR of 21.98% during the forecast period (2026–2034). North America dominated the AI in endoscopy market with a market share of 51.20% in 2025.
AI in endoscopy refers to AI-powered systems designed to assist physicians in detecting, characterizing, and diagnosing abnormalities during endoscopic procedures. These solutions use machine learning, deep learning, and real-time image analysis to enhance visualization, improve lesion detection, and support clinical decision-making.
The AI in endoscopy market demand is increasing due to the growing prevalence of gastrointestinal disorders, rising adoption of minimally invasive procedures, and increasing focus on early disease detection. Healthcare providers are adopting AI-enabled endoscopy systems to improve diagnostic accuracy and reduce missed lesions. Advances in AI technology, increasing awareness of AI-assisted diagnostics, and supportive regulatory developments are also contributing to market growth.
Download a Free Sample to Explore Detailed Market Insights
The AI in endoscopy market has indirect exposure to supply chain disruptions due to its dependence on advanced imaging components, chips, sensors, processors, and specialized medical device manufacturing. Global disruptions in the supply of electronic components, logistics networks, and raw materials have increased production costs, extended equipment delivery timelines, and delayed the deployment of AI-enabled endoscopy systems across healthcare facilities. These challenges have also affected technology integration and product availability, influencing procurement decisions and slowing adoption. Despite these constraints, the market is demonstrating a capacity-constrained recovery, supported by improving semiconductor supply, expanding manufacturing capabilities, and sustained investments in healthcare digitalization.
Healthcare providers are increasingly integrating AI into endoscopy workflows to enable real-time detection of polyps, adenomas, and early-stage gastrointestinal lesions during procedures. This transition from conventional visual inspection to AI-assisted image analysis is improving diagnostic confidence, reducing missed lesions, and supporting standardized clinical outcomes. The trend is accelerating the adoption of intelligent endoscopy systems across hospitals and ambulatory surgical centers.
Healthcare institutions are increasingly integrating AI analytics with cloud-based endoscopy data platforms to improve workflow efficiency, quality monitoring, and clinical decision-making. This transition from standalone systems to connected digital ecosystems is strengthening interoperability and accelerating digital endoscopy adoption.
The AI in endoscopy market forecasts sustained investment activity, driven by the increasing adoption of AI-assisted diagnostics, rising demand for early gastrointestinal disease detection, and continued digital transformation across endoscopy services. Investors are prioritizing companies developing AI-powered image analysis platforms, cloud-enabled endoscopy ecosystems, and intelligent workflow solutions that enhance diagnostic accuracy and support precision medicine.
In October 2025, Surgical Automations announced the successful close of an oversubscribed USD 3.4 million seed funding round. The investment will support development and commercialization of the Vāsuki Robotic System, an AI-enabled robotic platform for gastrointestinal diagnostic and interventional endoscopy. The funding will also be used to advance product engineering and manufacturing readiness. This investment is expected to accelerate the adoption of AI-assisted robotic endoscopy technologies and support future commercial expansion.
Increasing Prevalence of Gastrointestinal Disorders & Colorectal Cancer Screening and Rising Regulatory Approvals for AI-assisted Endoscopy Solutions Drives Market
The rising incidence of gastrointestinal disorders and colorectal cancer is increasing demand for AI-assisted endoscopy systems. Healthcare providers are adopting AI solutions to improve adenoma detection rates and reduce missed polyps. This is accelerating the deployment of AI-enabled endoscopy across hospitals and ambulatory surgical centers. For example, the EU4Health-funded PRAISE-U initiative (2025) is supporting organized colorectal cancer screening programs across European countries, encouraging wider adoption of AI-assisted colonoscopy to improve screening quality and patient outcomes.
The growing number of regulatory approvals for AI-based endoscopy software is strengthening market confidence and accelerating commercialization of advanced technologies. Faster approvals enable healthcare providers to access clinically validated AI solutions that enhance workflow efficiency and diagnostic accuracy, increasing market demand. This is encouraging manufacturers to expand product portfolios and invest in innovation.
High Cost of AI-enabled Endoscopy Systems and Data Privacy Regulations Restrain Market Expansion
AI-enabled endoscopy systems require substantial investment in advanced endoscopes, AI software, cloud infrastructure, system integration, and clinician training. These high implementation costs limit adoption among small and mid-sized hospitals, particularly in emerging economies where healthcare budgets are constrained.
AI-based endoscopy solutions depend on large volumes of patient imaging data for training and clinical use. Strict data privacy regulations and evolving AI compliance requirements increase implementation complexity and lengthen product approval timelines. Consequently, these issues delay commercialization, limit data sharing, and restrain the adoption of AI-enabled endoscopy systems.
Expansion of AI-enabled Capsule Endoscopy and Rising AI Adoption for Barrett's Esophagus Surveillance Offer Growth Opportunities to Market Players
The growing adoption of capsule endoscopy is creating new opportunities for AI developers and endoscopy device manufacturers. AI algorithms can rapidly analyze thousands of images generated during capsule procedures, reducing physician workload and improving the detection of small bowel bleeding, Crohn's disease, and tumors. This opportunity is expected to accelerate the commercialization of AI-powered capsule endoscopy solutions. Companies such as AnX Robotica (Navicam) and Medtronic (PillCam) are expanding AI capabilities to strengthen their diagnostic platforms.
The increasing focus on early detection of esophageal cancer is creating growth opportunities for AI-powered upper gastrointestinal endoscopy solutions. AI-assisted systems improve the identification of dysplasia and early neoplastic changes in patients with Barrett's esophagus, enabling timely intervention and better clinical outcomes. This opportunity is encouraging technology providers to develop specialized AI applications for upper GI diagnostics. Companies such as PENTAX Medical and Olympus are expanding AI-supported imaging technologies to enhance Barrett's esophagus surveillance and upper GI cancer detection.
Limited Availability of High Quality Annotated Clinical Data and Difficulty in Integrating AI into Routine Clinical Workflow Challenges Market Growth
AI models require large volumes of diverse, accurately annotated endoscopic images to achieve consistent performance across different patient populations and disease types. However, obtaining standardized datasets remains challenging due to variations in imaging equipment, clinical practices, and annotation quality across healthcare institutions. This limits algorithm generalizability, slows product development, and delays broader clinical adoption of AI-enabled endoscopy systems.
Integrating AI solutions into routine endoscopy workflows remains a significant challenge due to differences in hospital IT infrastructure, endoscopy equipment, and clinical protocols. Healthcare providers must ensure seamless interoperability between AI software, imaging systems, and electronic health records without disrupting existing procedures. Additional workflow validation, staff training, and system optimization are often required before full-scale implementation, slowing adoption and limiting the widespread deployment of AI-enabled endoscopy technologies.
The AI-enabled devices segment accounted for a share of 48.34% in 2025, owing to their seamless integration with endoscopy hardware, real-time image processing capabilities, and immediate clinical usability during procedures. Their ability to operate without external computing infrastructure enables faster deployment, standardized performance, and higher preference among healthcare providers.
The AI software & platforms segment is expected to grow at a CAGR of around 22.71% during the forecast period, driven by the increasing demand for vendor-neutral compatibility, continuous algorithm updates through software releases, and scalable deployment across multi-hospital networks. These platforms also enable centralized analytics, workflow optimization, and subscription-based revenue opportunities.
In 2025, CADe accounted for a share of 65.76% due to its ability to provide real-time visual alerts, improve polyp detection consistency, and integrate easily into routine screening procedures. Its minimal workflow disruption has accelerated adoption across high-volume endoscopy centers.
The CADx segment is expected to grow at a CAGR of 22.43% during the forecast period, fueled by the rising demand for lesion characterization, optical biopsy support, and treatment decision assistance during endoscopic procedures. These capabilities reduce unnecessary tissue sampling while improving diagnostic confidence.
The gastrointestinal endoscopy segment accounted for a share of 63.27% in 2025, owing to high procedural volume, broad availability of AI-trained datasets, and established clinical workflows for colorectal and upper gastrointestinal examinations. These factors enable faster AI implementation and greater clinical acceptance.
The capsule endoscopy segment is expected to grow at a CAGR of 22.69% during the forecast period, boosted by increasing demand for automated image review, efficient small bowel lesion detection, and reduced physician interpretation time. AI significantly improves analysis efficiency for procedures generating thousands of diagnostic images.
Hospitals & clinics accounted for a share of 51.33% in 2025, supported by their access to multidisciplinary gastroenterology teams, advanced digital endoscopy infrastructure, and high patient throughput requiring efficient AI-assisted diagnostic workflows. These facilities also support large-scale deployment and continuous clinical validation.
The diagnostic imaging centers segment is expected to grow at a CAGR of 22.80% during the forecast period, fueled by expanding outpatient diagnostic services, increasing adoption of specialized AI-assisted screening programs, and growing demand for rapid reporting with optimized resource utilization. These centers benefit from scalable AI solutions that enhance operational efficiency.
North America: Market Dominance Led by Advanced Endoscopy Infrastructure and Growing Implementation of AI-enabled Endoscopy Platforms
The North America AI in endoscopy market accounted for the largest regional share of 51.20% in 2025, driven by widespread adoption of AI assisted gastrointestinal diagnostics, strong healthcare digitalization, and high colorectal cancer screening volumes. The region also benefits from advanced endoscopy infrastructure, favorable reimbursement policies, and rapid clinical integration of AI technologies.
The US AI in endoscopy market was valued at USD 1.28 billion in 2025, driven by increasing adoption of AI assisted polyp detection technologies, growing colorectal cancer screening initiatives, and rising investments in digital healthcare. Healthcare providers are implementing AI enabled endoscopy platforms to improve diagnostic accuracy, reduce missed lesions, and enhance procedural efficiency. The country's strong presence of leading AI developers, academic medical centers, and advanced gastroenterology networks continues to accelerate the adoption of intelligent endoscopy solutions.
The Canada AI in endoscopy market size was valued at USD 191.29 million in 2025, supported by expanding colorectal cancer screening programs, increasing investments in healthcare digital transformation, and growing adoption of AI assisted diagnostic technologies. Hospitals are integrating AI into endoscopy services to improve early disease detection, optimize clinical workflows, and address increasing demand for gastrointestinal care. The country's publicly funded healthcare system and emphasis on technology enabled diagnostics continue to support the adoption of AI powered endoscopy across major healthcare institutions.
Asia Pacific: Fastest Growth Driven by Rising Gastrointestinal Cancer Screening Programs and Strong Government Support for Digital Healthcare
The Asia Pacific AI in endoscopy market is expected to grow at a CAGR of 23.15% during the forecast period, showcasing the fastest regional growth. Growth is propelled by national gastrointestinal cancer screening programs, rising investments in AI enabled healthcare infrastructure, and improving access to advanced endoscopy services. Governments are prioritizing digital diagnostics to address growing disease burden.
The China AI in endoscopy market was valued at USD 164.06 million in 2025, supported by rapid expansion of domestic AI medical device innovation, increasing deployment of smart hospitals, and strong government support for digital healthcare. The country continues to integrate AI into hospital information systems and diagnostic services to improve healthcare efficiency. According to China's National Health Commission, more than 3,000 hospitals had achieved Smart Hospital maturity certification by 2025, creating favorable conditions for AI-enabled endoscopy adoption.
The India AI in endoscopy market size was valued at USD 83.92 million in 2025, fueled by expansion of domestic AI enabled medical device innovation, increasing availability of skilled gastroenterologists across private healthcare networks, and growing adoption of value-based healthcare models emphasizing diagnostic accuracy. Rising investments in indigenous health technology development and the integration of AI into tertiary care centers are further accelerating the adoption of AI assisted endoscopy solutions across the country.
The Japan AI in endoscopy market size was valued at USD 96.82 million in 2025, supported by technology innovation, early integration of AI into routine gastrointestinal practice, and strong collaboration between academic hospitals and medical device manufacturers for AI validation. The market also benefits from favorable reimbursement for AI assisted gastrointestinal diagnostics. The Japanese Society of Gastroenterology and the Japan Gastroenterological Endoscopy Society has expanded AI-focused clinical guidance and educational programs to promote standardized adoption of AI in gastrointestinal endoscopy, strengthening implementation of AI assisted diagnostic practices.
The AI in endoscopy market competitive landscape is moderately consolidated, with competition led by established endoscopy manufacturers, medical imaging companies, and AI software developers offering computer-aided detection and diagnostic solutions. Leading players compete through advancements in real-time image analysis, lesion detection accuracy, workflow integration, and regulatory approvals while strengthening partnerships with healthcare providers. The AI in endoscopy market ecosystem is shaped by rapid technological innovation, increasing adoption of digital healthcare, evolving clinical guidelines, and growing demand for early disease detection solutions that improve diagnostic accuracy, procedural efficiency, and patient outcomes.
May 2026: Olympus Corporation signed an exclusive global distribution agreement with EndoRobotics Co., Ltd. to commercialize robot-assisted endoscopic technologies.
October 2025: Olympus Corporation entered a strategic partnership with DigestAID to develop AI-powered Software-as-a-Medical-Device (SaMD) solutions for hepato-pancreato-biliary (HPB) diseases.
September 2025: Olympus Corporation launched the OLYSENSE CAD/AI platform in the US and Europe, expanding its cloud-based AI endoscopy ecosystem with computer-aided detection capabilities for gastrointestinal procedures.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com